A combined radioimmunoassay for the two thyroid hormones is described which uses '25iodine labelled triiodothyronine and l3liodine labelled thyroxine. The assay employs a double antibody separation technique and is suitable for use with unextracted serum. The results from the simultaneous assay compare very well with the results obtained in the single assays, and the discriminating power and precision of the simultaneous assay is at least as good as in the single assays.
A combined radioimmunoassay for the two thyroid hormones is described which uses '25iodine labelled triiodothyronine and l3liodine labelled thyroxine. The assay employs a double antibody separation technique and is suitable for use with unextracted serum. The results from the simultaneous assay compare very well with the results obtained in the single assays, and the discriminating power and precision of the simultaneous assay is at least as good as in the single assays.
The estimation of serum thyroxine (T4) is probably the most widely used single test of thyroid function. Over the last few years the measurement of serum triiodothyronine (T3) has been introduced and is rapidly becoming accepted as a measurement yielding useful information. In particular it is thought to be useful in detecting early hyperthyroidism (Burke and Eastman, 1974) , in establishing the diagnosis of T3 thyrotoxicosis (Sterling et al., 1970 , Hollander, et 01., 1972 , Shalet et 01., 1975 , and in assessing thyroid status in patients treated for thyrotoxicosis both as an indicator of a euthyroid state in the presence of a low T4 level (Hoffenberg, 1973) and in providing early biochemical evidence of relapse (Marsden et 01., 1975) . Many laboratories, including our own, now find themselves measuring serum T3 in an increasing proportion of samples sent for thyroid function tests, both for the specific reasons mentioned above and to clarify the position in any patient whose T4 result is equivocal. In an attempt to reduce the work involved and to reduce the turn-round time for the samples involved we have established an assay in which both T4 and T3 are measured simultaneously in the same aliquot of serum. A somewhat similar assay system has been previously described by Mitsuma et 01. (1972) .
This paper describes the simultaneous assay system developed and compares the results with those obtained in the single assays for T4 and T3 currently in routine use in the department.
MATERIALS AND METHODS

Single radioimmunoassays for T4 and T3
These were performed by the semiautomated methods of Challand et al. (1975) modified as necessary to use different sample volumes (50 flol for T4 and 100 flol for T3) and antibodies (see below). The modifications for the T4 assay included the use of 132 mg polyethylene glycol (PEG) per tube and 1020 flog of 8-anilino-I-naphthalene sulfonic acid (ANS) 12 per tube. The modifications for the T3 assay included the use of 200 flog ANS per tube, the use of donkey antigoat second antibody, and the omission of nonimmune carrier serum. The antibodies used for both assays were the same as in the simultaneous assay.
Simultaneous radioimmunoassay
MATERIALS
(1) Antisera. Sheep anti-T4 serum was kindly provided by Dr. T. G. Merrett. Goat anti-T3 serum was kindly provided by Dr. A. S. McNeilly. Both antibodies had been previously shown not to crossreact to a significant extent with T3 and T4 respectively.
(2) Standards. L-Thyroxine (sodium salt pentahydrate) and 3, 5, '5, triiodo-L-thyronine, both from Sigma Chemical Company. Appropriate amounts of each standard are dissolved in a few drops of 0.1 M NaOH and the volume made up to 50 ml with ethanol. Intermediate dilutions are then made with buffer, and small aliquots of these dilutions are added to 10 ml aliquots of hormone free serum to yield a range of working standards as follows: for T4 652, 326, 208, 163, 130, 65 , and 13 nrnol/l; for T3 12.3, 6.2, 3.1, 2.0, 1.23, 0.62, and 0.31 nmol/l. The bulk working standards are then divided into 300 flol aliquots, which are stored at -20 0 e until use.
Standards prepared in this way have been found to be stable for at least six months.
(3) Tracer hormones. 131I-L-thyroxine of specific activity 20-50 mCi/mg from the Radiochemical Centre. 125I-triiodothyronine of specific activity 500 mCi/mg from Abbot Radio-Pharmaceuticals. On arrival both tracers are diluted with 50% aqueous propylene glycol to give approximately 25 floCi/ml for the T4 and 4 floCi/ml for the T3. The diluted tracers are stored in the I ml aliqu ots at -20 DC.
(4) Second antibody. Donkey antigoat/sheep serum from Wellcome Reagents Limited. This antibody was shown to be satisfactory in precipitating both first antibodies without the addition of carrier immunoglobulin.
(5) 8-anilino-L-naphthalene sulfonic acid (ammonium salt) from Sigma Chemical Company.
(6) Barbitone buffer, 0.075 M pH 8.5 containing 0.1 % human serum albumin (Sigma Chemical Company).
(7) Hormone free serum, prepared by the method of Sekkade et al. (1973) . This method, involving adsorption using Dowex 2 resin (chloride form), was shown to reliably remove at least 98 % of both thyroid hormones.
ASSAY PROCEDURE
The assay is performed in 65 x 10 mm round bottomed polystyrene tubes (Sterelin Ltd.). Each assay tube contains: The tracer hormones, ANS, second antibody, and buffer are made up as a single reagent used to prime a Variable Diluter (Hook and Tucker Instruments Ltd.) set to sample \00 flol of standard or test and dilute with 800 flol of reagent. The T4 and T3 antisera are added separately, immediately after the sampling and dilution stage, as 100 flol aliquots in buffer using a Compupet (Warner Lambert Company). Total count tubes, antibody blank (zero standard), and diluent blank (no antibody, a check on nonspecific binding and precipitation) tubes are included in each assay. All tubes are set up in duplicate. The tubes are mixed on a Vortex mixer, incubated overnight at ambient temperature, and then centrifuged for 30 minutes at 3000 rpm. The supernatants are aspirated and the precipitates counted in an LKB Wal1ac 1280 Ultrogamma counter in the dual isotope mode. Counts in excess of 10 000 are collected for each tube. Standard curves are plotted (per cent tracer bound versus log hormone concentration), and test results are read against these.
assays being 20-25 % as opposed to 30-35 % in both single assays. The reasons for this reduced binding are discussed below.
A comparison was made between the results obtained in the simultaneous assay and the results obtained in single assays. For this purpose a total of 342 sera, from hypothyroid, normal, and thyrotoxic patients, were assayed for both hormones by both methods. The samples were split into 15 batches and the assays performed on 15 different days over a four-month period. Low, normal, and high serum pools were included for each T4 assay and normal and high serum pools for each T3 assay. Analysis of the results showed a good agreement between the two assay methods. T3 results obtained in the simultaneous assay (y) correlated well with those obtained in the single assay (x), r = 0.92, and y = 0.82 x + 0.22. For the T4 results the comparable figures were, r = 0.88, and y = 0.88 x + 19. The relationship between the results for both hormones in the single and simultaneous assays is shown in Figs. I and 2. In these figures the data have been pooled to facilitate the representation of 342 pairs of results. Thus the mean of al1 single T4 assay results of less than 50 nrnol/l has been calculated and plotted against the mean of the simultaneous assay T4 values for the same samples. Corresponding points are plotted for means of single assay T4 values in the ranges of 51-100, 101-150, 151-200, 201-250 , and greater than 250 nmol/l, For the T3 results the data have been similarly pooled into the ranges less than 0.5, 0.51-1.0, 1.01-1.5, 1.51-2.0, 2.01-2.5, 2.51-3.0, and greater than 3.0 nmol/l.
The precision of the simultaneous assay was assessed by analyses of the results of the serum pools The conditions used for the simultaneous assay yielded standard curves in which the binding of tracer was consistently less than in the single assays, binding in the zero standards in the simultaneous included in each of the 15 individual comparative assays. Within-batch precision, for values in the normal range expressed as a coefficient of variation, was shown to be of the order of 6 % for the T4 estimations and 7 % for the T3 estimations. The between-batch precision for both assays is shown in Table 1 , where it is compared with the comparable figures for the individual assays. Reference ranges for the simultaneous assay were calculated from the results of 167 euthyroid adults (age 18-74 years, 71 male and 96 female, none of the females being pregnant or taking oral contraceptives). The results were normally distributed and gave reference values, calculated as mean ± two standard deviations, of 0.58-2.00 nmol/l for serum T3 and 62-163 for serum T4. The single assay reference ranges, calculated in the same way were 0.56-1.98 nmol/l for serum T3 and 50-158 nmol/l for serum T4. Thus the simultaneous and single assays yielded very similar reference ranges except in the case of the lower limit for T4, when the calculated lower limit was 12 nmol/l higher in the simultaneous assay than in the single assay. To test if this difference was associated with any difference in discriminating ability the 58 patients with T4 values below 80 nmol/l in either assay were reviewed. Of these patients 11 had been finally judged to be hypothyroid and 47 euthyroid. The hypothyroid patients all had T4 levels below 50 nmol/I in the single assay and 10 of 11 had T4 levels below 62 nmol/I in the simultaneous assay (the level in the remaining patient being 63 nmol/l), Of the 47 euthyroid patients, 45 had T4 levels greater than 50 nmol/I in the single assay (levels in the other two being 41 and 45 nrnol/l), and 46 had T4 levels greater than 62 nmol/I in the simultaneous assay (the level in the remaining patient being 58 nmol/l). An assessment was also made of the discriminatory powers of both T4 and T3 as measured by both methods in the euthyroid/hyperthyroid region. For this purpose 43 patients with T4 values greater than 150 nmol/l in either assay were reviewed. Of these 21 patients had been finally judged to be thyrotoxic and 23 euthyroid. Of the thyrotoxic patients 19 had T4 levels above 163 nmol/l in the simultaneous assay and 20 had T4 levels above 158 nmol/I in the single assay. Of the euthyroid patients 7 had T4 levels above 163 nmol/l (highest 185) in the simultaneous assay and the same number had T4 levels above 158 nmol/I (highest 173) in the single assay. Twenty of the 21 thyrotoxic patients had T3 levels greater than 2.0 nmol/l in the simultaneous assay and greater than 1.98 in the single assay, the levels in the misclassified patients being 1.96 and 1.86 nmol/l respectively. Of the euthyroid patients only one had an abnormal T3 level, a level of 3.03 nmol/l in the single assay.
DISCUSSION
The design of the simultaneous assay system is essentially a compromise, as a common sepal ating system and a common ANS concentration have to be accommodated. It was found that it was not practicable to use the same dilutions for both the T4 and T3 antibodies as were used in the single assays, as the optimum second antibody concentrations were different. However it was established that if the dilution of the T4 antibody was increased twofold this still gave a satisfactory dose response curve, and the same second antibody concentration was then optimum for both antibodies. This manoeuvre resulted in a reduction in initial binding (i.e., in the antibody blanks) as described in the results section. Similarly the minimum ANS requirements for the two systems were different, and it was found that using the necessary amount of ANS for the T4 component of the system (2 mg/loo iLl sample) also resulted in a reduction in the initial binding of T3. This high ANS concentration might be expected to lead to an overestimate of T3 concentrations, because of ANS competitive binding 10the antibody (Fang and Refetoff, 1974) in samples with low thyroxine-binding globulin concentrations, such as samples from patients with thyrotoxicosis (Oppenheimer, 1968) . In practice the good agreement between the estimates of T3 concentrations and the close similarity of the normal ranges found in assays with low and high ANS concentrations is good evidence that this effect is of little importance, at least for T3 values that are normal or near normal. However, the finding of a higher mean T3 level in the high pool serum (Table 1) suggests that this effect could be operative in the thyrotoxic range.
The ability of the two forms of the various assays to distinguish between normal and abnormal patients appears to be very similar, and we therefore conclude that the slight differences in reference values are not associated with any changes in discriminating power.
The data presented in Table 1 show that in spite of the reduced binding in the simultaneous assay satisfactory assay precision was still achieved. Indeed in the case of the low T4 pool the simultaneous assay showed a marked improvement in precision over the single assay. The reason for this is not entirely clear but is probably attributable either to the change in antibody dilution or to the change in separation technique.
The widespread use of simultaneous assays for T3 and T4 would add significantly to the costs of thyroid function testing, as many T3 reagents ale relatively expensive, particularly high specific activity l25IT3. It is debatable whether or not these extra costs are justifiable. It can be argued that it would be wasteful to perform on all samples a test that is currently done on less than 25 % of samples (at least in our laboratory). On the other hand there would be potential savings in labour costs by eliminating a separate T3 assay, and a shorter turn-round time in the laboratory may reduce the length of some patients' stay in hospital. We are of the opinion that this question can be resolved only by introducing the simultaneous assay into our routine for a limited period and carefully assessing the consequences.
